CARP has been involved in challenging changes to pharmacare in Nova Scotia and in Ontario and other provinces. The concern was that higher-income elders would have to pay higher premiums. What were the exact proposed changes that CARP decided to challenge? Why has the approach of increased premiums on elderly Canadians failed to address the increasing cost of pharmaceuticals in Canada, and how could a national pharmacare strategy overcome this problem?
On June 1st, 2016. See this statement in context.